Abstract
Antiviral Therapeutics: Pipelines and Competitive Dynamics assesses the compounds, the clinical data, the companies, and the market-shifting developments in the antiviral therapeutic category. Sales of antiviral agents currently constitute 25% of the anti-infective drug market. The ability of viruses to develop resistance against drugs, coupled with sub-optimal treatment outcomes as a result of failure of patients to comply with the full course of therapy, will continue to provide the commercial and medical incentive for intense R&D activity.
Until recently, much of the effort to develop new antiviral agents was directed toward improved agents for the treatment of HIV and Hepatitis C (HCV). While these indications continue to attract research dollars and to make measurable progress with respect to dosing, deliverability, and efficacy, several new developments have reignited interest in antiviral disease R&D. These include concern about the evolution of avian influenza into a lethal pandemic and recent approvals for vaccines against certain strains of Human Papilloma Virus (HPV) that are associated with high rates of cervical cancer.
Antiviral Therapeutics: Pipelines and Competitive Dynamics surveys the 5 major viral disease categories and their sub-indications- HIV, Hepatitis, Herpes Viruses, Human Papilloma Viruses, and Respiratory Viruses.
For each indication, the report provides:
- Pathophysiology, incidence and prevalence, symptoms and sequelae.
- Assessment of current treatment options.
- Assessment of unmet medical need.
- Assessment of compounds in development (by agent and by mechanism of action).
- Profiles of companies active in antiviral R&D
Table of Contents
Chapter 1. Viral Disorder and Therapeutic Approaches
- 1.1. Commom Viral Infections
- 1.2. Vaccines or Antiviral Drugs
- 1.3. Inhibition of Viral Infection of Cells
- 1.4. Inhibition of Viral Processing
Chapter 2. Review of Major Viral Disorders
- 2.1. Human Immunodeficiency Virus
- 2.2. Hepatitis Viruses
- Hepatitis A
- Hepatitis B
- Hepatitis C
- 2.3. Herpes Viruses
- Herpes Simplex Virus
- Varicella-Zoster Virus
- Cytomegalovirus
- Epstein-Barr Virus
- 2.4. Human Papilloma Virus
- 2.5. Respiratory Viruses
- Influenza
- Respiratory Syncytial Virus
- Coronaviruses
Chapter 3. Current Treatment
- 3.1. Human Immunodeficiency Virus
- HIV Reverse Transcriptase Inhibitors
- HIV Protease Inhibitors
- HIV Fusion Inhibitors
- 3.2. Hepatitis Viruses
- Vaccine Treatments
- Cytokines
- Antiviral Agents
- 3.3. Herpes Viruses
- Viral Replication Inhibitors
- 3.4. Human Papilloma Viruses
- 3.5. Respiratory Viruses
- Vaccines
- Neuraminidase Inhibitors
- Antibodies
- Inosine Monophosphate Dehydrogenase Inhibitors
Chapter 4. Compounds in Development: New Antiviral Agents
- 4.1. Human Immunodeficiency Virus
- HIV Protease Inhibitors
- Reverse Transcriptase Inhibitors
- Cell Entry Blockers
- HIV Replication Inhibitors
- HIV Integrase Inhibitors
- HIV Maturation Inhibitors
- Combination Therapies
- 4.2. Hepatitis C
- HCV Protease Inhibitors
- Polymerase Inhibitors
- Immunostimulants: Interferons
- Toll-like Receptor Agonists
- Other Immunoregulators
- Viral Replication Inhibitors
- 4.2. Mechanistic Issues in Atherogenic Dyslipidemia
- Anti-Atherogenic Effects of High-Density Lipoprotein
- Metabolic Syndrome, High-Density Lipoprotein, and Triglycerides
- 4.3. Hepatitis B
- DNA Polymerase Inhibitors
- Other Agents
- 4.4. Herpes Viruses
- Vaccines
- Viral Replication Inhibitors
- Viral Uptake Inhibitors
- DNA Synthesis Inhibitors
- Other Agents
- 4.5. Human Papilloma Viruses
- Vaccines
- Interferons
- Immunomodulators
- 4.6. Influenza
- New Drugs
- New Vaccines
- H5N1 Influenza Vaccines
Chapter 5. Company R&D Profiles
- 5.1. Abbott
- 5.2. Achillion
- 5.3. Boehringer Ingelheim
- 5.4. Biota Holdings
- 5.5. Bristol-Myers Squibb
- 5.6. Chiron
- 5.7. Coley
- 5.8. Enzo Biochem
- 5.9. Gilead Sciences
- 5.10. GlaxoSmithKline
- 5.11. Hoffmann-La Roche
- 5.12. Idenix Pharmaceuticals
- 5.13. Japan Tobacco
- 5.14. Johnson & Johnson
- 5.15. Medivir
- 5.16. Merck & Co.
- 5.17. Novartis AG
- 5.18. Panacos Pharmaceuticals
- 5.19. Pfizer
- 5.20. sanofi pasteur
- 5.21. Schering-Plough
- 5.22. Trimeris
- 5.23. Valeant
- 5.24. Vertex
- 5.25. ViroPharma Incorporated
Chapter 6. EXPERT INTERVIEWS: Dr. Michael G. Cordingley, Boehringer Ingelheim (Canada) Ltd.; Dr. Stef Heylen, Tibotec; Professor Bertil Samuelsson, Medivir AB
- 6.1. HIV
- 6.2. Hepatitis
- 6.3. Other Viral Infections
- 6.4. Other Issues
